A $24-million funding round promises exciting developments ahead for Eupry

We are thrilled to announce that we at Eupry have closed a Series A funding, raising $24 million and welcoming the renowned investment company Chr. Augustinus Fabrikker who is joining our existing investor group. The investment will enable us to enhance our product offerings to cover even more of our client’s needs.

By: Christian Jacobsen, CEO at Eupry

At Eupry, our hardware and software solutions bring together three compliance industries, validation, monitoring, and calibration, into one, which enables highly regulated sectors such as pharmaceutical, biotech, and logistics to digitize processes that have traditionally been manual and risk-filled – and the global demand for our solutions has now resulted in a funding round of 24 million USD and welcoming Chr. Augustinus Fabrikker, who is joining our current investor team Ugly Duckling Ventures, EIFO, and Sagitta in this round.

The investment is not just a financial boost but also an endorsement of our vision to rethink compliance procedures and enable digitalization in the world’s most regulated industries.

We want to change – and are changing – the way pharmaceutical and other critical products are handled and do away with scattered legacy processes that come with risks and valuable time going away from innovation. This investment sends a clear signal that our investors believe in and support this vision. Something we are both grateful for and humbled by.

The future of pharma – developing digital solutions for industries that do not really digitalize

Since the beginning, we have focused on developing digital products for industries like pharmaceutical logistics and manufacturing, characterized by high regulatory requirements and legacy processes and systems that can be difficult to replace.

In other words, sectors where digitalization has been a challenge.

Therefore, the reliability and innovation of our product have always been our main priority. For several years, we dedicated our primary resources to developing our technology instead of focusing on growth, leading to breakthroughs like our patented calibration technology, which reduces average process time by up to 80%.

This dedication to our product will remain a central focus, and the investment will provide essential support.

Although these regulated industries have progressed further in digitization, it is still an underserved market. We are fortunate to work with some of the world's largest pharmaceutical and logistics companies, and despite their size, they struggle to find solutions that truly meet their needs.

Therefore, there is significant potential for working on product development. That's why we are also bringing on board a group of talented individuals to help expand our product portfolio so we can address even more of the needs our customers face.

Most importantly: A thank you

I want to express our deepest gratitude to Chr. Augustinus Fabrikker, Ugly Duckling Ventures, Sagitta, and EIFO, thank you for supporting us. Their belief in our mission and commitment to our success is invaluable.

Last but not least, to the entire Eupry team, this achievement is a testament to your hard work and dedication. Each of you plays an important role in our success, and this milestone is a collective triumph that we should all be proud of.

As we embark on this new chapter, I am more confident than ever in our ability to lead the transformation in temperature compliance. The future holds incredible opportunities, and with our robust solutions and strong support from our investors, Eupry is well-positioned to seize them.

Here is to achieving greater heights and continuing to innovate for a safer, more efficient world.

/ Christian Jacobsen, CEO and co-founder of Eupry

What some of our investors say

"We have been following Eupry for a long time and are impressed by their innovative temperature monitoring and data management solutions, which are now set to anchor on a global scale. We see tremendous potential in Eupry and are pleased and proud to welcome them to Chr. Augustinus Fabrikker — and contribute to their further journey. With their groundbreaking products, ambitions, and a skilled and dedicated team, Eupry fits perfectly into our scale investment strategy, and we look forward to unlocking the potential together with Eupry, EIFO, Ugly Duckling Venture, and Sagitta." Claus Gregersen, CEO of Chr. Augustinus Fabrikker.

"EIFO and Chr. Augustinus Fabrikker works together in several Danish growth companies. We know them as one of the Danish investors who are best at creating change within venture growth. They have an incredibly strong network and can significantly contribute to the scaling up of their portfolio companies. Therefore, we see it as a very positive development for Eupry that they are now entering the ownership circle." Mads Lacoppidan, Partner & Head of Life Science at EIFO.

"After nearly two years as the company's Chairman of the Board, I could not be more proud of this preliminary highlight for Eupry. It has been a fantastic joint effort, and we look forward to creating the next big Danish life science-related success with a strong co-investor in Chr. Augustinus Fabrikker." Andreas Green Rasmussen, Ugly Duckling Ventures co-founder and chairman of the board at Eupry.